Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment
Phase 2
Not yet recruiting
- Conditions
- Castration-Sensitive Prostate CancerMetastatic Prostate Cancer
- Interventions
- Drug: apalutamideDrug: androgen deprivation therapyProcedure: cytoreductive radical prostatectomy with/without pelvic lymph node dissectionRadiation: metastasis-directed therapy with radiation
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 47
- Registration Number
- NCT05717582
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center Pudong Hospital, Shanghai, Shanghai, China
🇨🇳Fudan University Shanghai Cancer Center Xuhui Hospital, Shanghai, Shanghai, China
Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012)
Phase 3
Recruiting
- Conditions
- Lung AdenocarcinomaSegmentectomy
- Interventions
- Procedure: Segmentectomy
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 307
- Registration Number
- NCT05717803
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Application of "Heidelberg Triangle" Dissection in Pancreatoduodenectomy and Distal Pancreatectomy
Recruiting
- Conditions
- Periampullary CarcinomaPancreatoduodenectomyPancreatic Cancer
- Interventions
- Procedure: TRIANGLE operation
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 200
- Registration Number
- NCT05703581
- Locations
- 🇨🇳
Huadong Hospital affiliated to Fudan University, Shanghai, China
Dosimetric Limitation of Pelvic Bone and Peritoneal Space in Rectal Cancer Patients During Chemoradiotherapy
Not Applicable
Active, not recruiting
- Conditions
- Rectal Cancer
- Interventions
- Radiation: dosimetric limitation of pelvic bone and peritoneal space during radiotherapy
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 200
- Registration Number
- NCT05688033
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma
Phase 1
Recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2023-03-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 25
- Registration Number
- NCT05675462
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA After One Cylce Neoadjuvant Chemotherpy
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 366
- Registration Number
- NCT05674305
- Locations
- 🇨🇳
Fudan Universtiy Shanghai Cancer Centre, Shanghai, Shanghai, China
Anatomical Resection in Colorectal Liver Metastases Patients
Completed
- Conditions
- The Characteristics of CRLM Patients Who Would Benefit More From Anatomical Resection
- Interventions
- Procedure: Anatomical Resection
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 729
- Registration Number
- NCT05673564
Effect of Huaier Granule on Nephrotoxicity Associated With Targeted Therapy for Advanced Hepatobiliary Malignancies.
Phase 4
Recruiting
- Conditions
- Nephrotoxicity
- Interventions
- Drug: Huaier GranuleDrug: VEGFR-TKIs
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 53
- Registration Number
- NCT05673824
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC Patients
Phase 2
Recruiting
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- Drug: Camrelizumab+cetuximab+chemotherapy
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 40
- Registration Number
- NCT05673577
- Locations
- 🇨🇳
Fudan University, Shanghai, China
a Study of Combined mpMRI and PSMA PET/CT for Highly Suspicious Patients Performing Radical Prostatectomy Without Biopsy
Not yet recruiting
- Conditions
- Prostate BiopsyProstatic NeoplasmsProstatectomy
- First Posted Date
- 2023-01-04
- Last Posted Date
- 2023-01-11
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 71
- Registration Number
- NCT05670691
© Copyright 2025. All Rights Reserved by MedPath